NCT01076491

Brief Summary

This study is to investigate the safety and tolerability of high doses of inhaled mannitol in subjects with bronchiectasis to further direct development of an improved drug delivery system.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Jan 2009

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2009

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2009

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2009

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

November 11, 2009

Completed
4 months until next milestone

First Posted

Study publicly available on registry

February 26, 2010

Completed
Last Updated

February 26, 2010

Status Verified

February 1, 2010

Enrollment Period

2 months

First QC Date

November 11, 2009

Last Update Submit

February 24, 2010

Conditions

Outcome Measures

Primary Outcomes (1)

  • emitted dose

    single measure

Interventions

inhaled mannitol - single doses of either 70 mg or 90 mg

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • adult subjects with non-CF bronchiectasis
  • FEV1 \> 50 % predicted and \> 1.0L

You may not qualify if:

  • bronchiectasis due to CF or endobronchial lesion
  • respiratory infection requiring IV antibiotics in last 4 weeks
  • pregnancy
  • significant haemoptysis in last 6 months
  • active TB
  • end stage ILD
  • contraindications as determined by investigator

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Royal Prince Alfred Hospital

Sydney, New South Wales, 2050, Australia

Location

MeSH Terms

Conditions

Bronchiectasis

Interventions

Mannitol

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Sugar AlcoholsAlcoholsOrganic ChemicalsCarbohydrates

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

November 11, 2009

First Posted

February 26, 2010

Study Start

January 1, 2009

Primary Completion

March 1, 2009

Study Completion

April 1, 2009

Last Updated

February 26, 2010

Record last verified: 2010-02

Locations